Long-term post-menopausal hormone therapy and serum HDL-C, total cholesterol and triglycerides

Area of Science:

• Endocrinology
• Cardiovascular Health
• Menopause Research

Background:

• Hormone replacement therapy (HRT) is commonly used by post-menopausal women.
• The effects of different HRT formulations on lipid profiles, particularly high-density lipoprotein (HDL) cholesterol, require detailed investigation.
• Understanding these effects is crucial for assessing cardiovascular risk in women undergoing HRT.

Purpose of the Study:

• To evaluate the impact of long-term oral hormone replacement therapy on serum lipid concentrations in post-menopausal women.
• To compare the effects of oestradiol valerate, oestriol succinate, and a combination of oestradiol valerate with norgestrel on HDL cholesterol, total cholesterol, and triglycerides.

Main Methods:

• A study involving 158 post-menopausal women divided into four groups: oestradiol valerate, oestriol succinate, oestradiol valerate plus norgestrel, and a control group receiving no hormone therapy.
• Serum concentrations of HDL cholesterol, total cholesterol, and triglycerides were measured.
• Therapy durations were recorded for each treatment group.

Main Results:

• Oestradiol valerate therapy significantly increased HDL cholesterol levels compared to controls and the combination therapy group.
• Oestriol succinate therapy did not significantly alter HDL cholesterol levels compared to controls.
• Combination therapy with oestradiol valerate and norgestrel resulted in lower HDL cholesterol and triglyceride levels compared to controls.

Conclusions:

• Long-term oral oestradiol valerate therapy positively influences HDL cholesterol levels in post-menopausal women.
• The addition of norgestrel to oestradiol valerate therapy may negate the beneficial effects on HDL cholesterol and reduce triglyceride levels.
• Different HRT formulations have distinct effects on lipid profiles, necessitating individualized treatment approaches.